

Fast-tracking cancer treatments

linear

*How Linear streamlines world-first
oncology trials and treatments.*



Cancer is relentless. Its progress can be as swift as it is arbitrary. Time, then, is the biggest enemy for patients fighting cancer, as well as the biotech companies and medical innovators pioneering new oncology therapies.

As Western Australia's only dedicated Phase 1 unit, it's our mission to fast-track the development of life-changing therapies, which includes giving the people of WA access to those therapies. We've invested heavily in our first-in-patient capabilities and resources, particularly in Oncology where we have a wealth of specialist expertise and experience.

However, it's our ability to manage time, as well as complex oncology trials, that enables us to bring ground-breaking cancer therapies to fruition faster – not only for our global clients, but also for local patients who are out of conventional treatment options.

Oncology at Linear

Our oncology unit is home to a team of specialist consultants and an on-site fellow, as well as specialist oncology nursing, clinical and laboratory staff, with a collaborator network that spans the globe. That's why we're the oncology trial partner of choice for a growing number of sponsors.

It means we're continually assisting with the development of new cancer therapies that will benefit patients around the world. But it also means we're able to give local cancer patients – patients who have exhausted standard treatment options – access to novel, potentially life-saving therapies.

“Linear was an obvious choice for our phase 1 study based on their track record of exceeding recruitment targets, access to world class experts such Professor Michael Millward, and dedication to investing in quality training, infrastructure and patient safety.”

CBT Pharmaceuticals

Saving time, saving lives

Clearly, the health of cancer patients can deteriorate rapidly, so streamlining the recruitment process and matching patients and trials in a timely manner is critical. The faster the process, the faster we can give patients new treatments and help sponsors develop and refine their therapies.

Our solution to this challenge is - in true Linear style - the result of open collaboration.

By leveraging our state-wide collaborator and investigator network, we've developed a dynamic recruitment methodology and process that ensures we're able to rapidly and seamlessly match cancer patients with places on our oncology trials, thereby minimising or eliminating delays for sponsors and patients alike, no matter how complex the trial.

- + State health service partnerships
- + Collaborations with local consultants
- + Active, integrated patient database
- + Streamlined recruitment process
- + Seamless, fast-track trials
- + Timely access to novel therapies for patients

Case study: First-in-human PARP inhibitor study

Cancers: Ovarian, endometrium, small-cell lung cancer, glioblastoma

- + PARP inhibitor targeting solid tumours
- + 10 patients in the escalation phase
- + 4 patients in the expansion phase

Fifty percent of patients on the escalation phase received treatment up to 9 months. One patient received treatment for 17 months. One patient is continuing treatment beyond 24 months, achieving a partial response and stability for several months.

Case study: First-in-human B-Raf inhibitor study

B-Raf inhibitor targetting specific solid tumours

- + 5 patients in the expansion phase
- + 2 patients completed 4 cycles
- + 1 patient completed 8 cycles
- + 1 patient completed 14 cycles
- + 1 patient exceeded 23 cycles

Some patients achieved a good partial response, while the cancer stabilised in others.

Case study: First-in-human combination therapy study

Anti- PD-1 monoclonal antibody and a PARP inhibitor

- + 8 patients enrolled to date
- + Most patients remained on treatment beyond cycle 4
- + 1 patient achieved a completed response – all of their tumour lesions had disappeared

Recruitment was very competitive, with several sites in Australia competing for spots for patients. We were the first site to secure ethics approval for this study, so we had a head start in recruiting and managed to get the first three spots for our patients.

Case Study: First-in-human PD-1 inhibitor

- + 40 patients enrolled to date
- + Some patients continue up to cycle 6
- + A record number of patients recruited to an oncology study

Results for this study were presented at ASCO in May 2016.

At any one time, we have over 20 oncology trials underway.

Our outcomes

We consistently exceed our recruitment targets, which ultimately enables us to provide high quality data for sponsors in a timely manner. Just as importantly, we've opened the door to innovative therapies for local patients who have no other options.

+ We consistently exceed our recruitment targets.

While some trials don't progress beyond Phase 1 or Phase 2 studies, some of our patients have seen their disease stabilise, enabling them to participate in other trials or even return to chemotherapy.

Even with relatively low dosage levels in the escalation phase (where we're determining toxicity and maximum doses), we've had patients experience positive responses. And in some cases, the response to a new therapy has exceeded all expectations.

Find out more about how we'll use our extensive oncology resources and experience to add value to every stage of your cancer trial, from study design, to meeting or exceeding recruitment targets, to your final report. Contact our Oncology team directly at oncology@linear.org.au

+61 (0) 8 6382 5100

info@linear.org.au

www.linear.org.au

linear

*nurturing
medical
breakthroughs*